Activin Receptors, Type II
"Activin Receptors, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS. They are membrane protein kinases belonging to the family of PROTEIN-SERINE-THREONINE KINASES. The major type II activin receptors are ActR-IIA and ActR-IIB.
Descriptor ID |
D030301
|
MeSH Number(s) |
D08.811.913.696.620.682.700.062.750 D12.776.543.750.750.400.820.500.750
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type II".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type II".
This graph shows the total number of publications written about "Activin Receptors, Type II" by people in this website by year, and whether "Activin Receptors, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 2 | 2 | 4 |
2004 | 0 | 1 | 1 |
2005 | 2 | 0 | 2 |
2007 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 2 | 2 |
2013 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2020 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
2022 | 2 | 2 | 4 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Activin Receptors, Type II" by people in Profiles.
-
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 2023 11; 37(11):2314-2318.
-
Germline genetic mutations in pediatric cerebrovascular anomalies: a multidisciplinary approach to screening, testing, and management. J Neurosurg Pediatr. 2023 03 01; 31(3):212-220.
-
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with?ring sideroblasts. Blood. 2022 11 17; 140(20):2170-2174.
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2022 01 27; 139(4):624-629.
-
Endometrial receptivity and implantation require uterine BMP signaling through an ACVR2A-SMAD1/SMAD5 axis. Nat Commun. 2021 06 07; 12(1):3386.
-
miR-18a Inhibits BMP4 and HIF-1a Normalizing Brain Arteriovenous Malformations. Circ Res. 2020 10 09; 127(9):e210-e231.
-
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 01 09; 382(2):140-151.
-
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun. 2016 11 29; 7:13650.
-
The role of myostatin and activin receptor IIB in the regulation of unloading-induced myofiber type-specific skeletal muscle atrophy. J Appl Physiol (1985). 2015 Sep 15; 119(6):633-42.